No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
No Data
Rising Drug Costs Force a Third of Americans to Leave Prescriptions Unfilled: Report
AbbVie Insiders Sold US$56m Of Shares Suggesting Hesitancy
AbbVie, Genmab Blood Cancer Therapy Endorsed in EU
AbbVie (ABBV.US) has reached a $250 million acquisition agreement and obtained a potential first-in-class therapy.
Recently, AbbVie (ABBV.US) announced the acquisition of Celsius Therapeutics for a total consideration of USD 250 million.
AbbVie's (ABBV) Celsius Therapeutics Deal to Boost IBD Presence
AbbVie Completes Acquisition of Celsius Therapeutics for $250m